Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
6420
Trial Sponsor
Clinical Trial Start Date
September 8, 2021
0Primary Completion Date
December 22, 2021
0Study Completion Date
April 22, 2022
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Intervention Name
SARS-CoV-2 rS Nanoparticle Vaccine in-clinic mixed with Matrix-M1 Adjuvant0
qNIV Nanoparticle Vaccine2 in-clinic mixed with Matrix-M1 Adjuvant0
ICC Vaccine0
Interventional Trial Phase
Phase 20
Phase 10
Participating Facility
Official Name
A Phase 1/2, Randomized, Observer-Blinded Study to Evaluate the Safety and Immunogenicity of a Quadrivalent Hemagglutinin Nanoparticle Influenza and SARS-CoV-2 rS Nanoparticle Combination Vaccine With Matrix M1™ Adjuvant in Healthy Participants ≥ 50 to ≤ 70 Years of Age0
Last Updated
July 22, 2022
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Triple0
Masked Party
Investigator0
Care Provider0
Participant0
Study summary
This is a randomized, observer-blinded, Phase 1/2 study evaluating the safety and immunogenicity of a quadrivalent HA nanoparticle influenza and SARS-CoV-2 rS nanoparticle combination vaccine with Matrix-M1 adjuvant; this combination is referred to as ICC vaccine.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
